Intensive Care Foundation Research Free Paper Presentations Tuesday, December 9, 2014 CAPITAL SUITE ROOMS 2-4 Physiological and biochemical responses to fluid bolus therapy with 4% versus 20% human albumin solution in critically ill adults J Bannard-Smith, N Glassford, P Alexander, MJ Chan, BT Wong, M Lee, G Crawford, M Bailey, R Bellomo
The novel biased apelin receptor agonist MM07 is a potent inotrope and vasodilator in vivo AL Brame, JJ Maguire, A Dyson, M Singer, IB Wilkinson, AP Davenport
Healthcare cost trajectories before and after critical illness: a national data linkage cohort study NI Lone, TS Walsh
Glucose-insulin-potassium infusion for non-ischaemic cardiogenic shock: a proof of concept study TAC Snow, M Singer
P4 immunotherapy augments phagocyte bacterial killing in patients admitted to critical care with severe community-acquired pneumonia (abstract not available) B Morton, S Gore, M Bangert, E Dearing, R Parker, ID Welters, A Wright, G Rajam, EW Ades, A Kadioglu, SB Gordon
Superantigens in sepsis: effective treatment of staphylococcal enterotoxin B intoxication in the mouse (abstract not available) S Whitfield, C Green, J Risdall, C Taylor, A Carter, G Griffiths
16
The State of the Art 2014 Meeting
Research free paper presentations
Physiological and biochemical responses to fluid bolus therapy with 4% versus 20% human albumin solution in critically ill adults J Bannard-Smith*, N Glassford*†, P Alexander*, MJ Chan*, BT Wong*, M Lee*, G Crawford*, M Bailey†, R Bellomo* *Austin Health, Victoria, Australia. †Monash University, Alfred Hospital, Melbourne, Victoria, Australia Fluid bolus therapy (FBT) is common in critically ill patients. With the exception of traumatic brain injury, FBT with human albumin solution (HAS) appears safe and perhaps superior in severe sepsis.1 We aimed to compare the physiological and biochemical effects of FBT with 4% vs 20% HAS in critically ill adults. In a retrospective observational study at our tertiary intensive care unit, we obtained data for 202 critically ill patients receiving FBT with either 4% (n=101) or 20% (n=101) HAS according to clinician preference. We compared sequential biochemical and haemodynamic data at baseline, one, two and four hours after the administration of either 4% or 20% HAS. Patients receiving 20% HAS were generally sicker, with a higher incidence of pre-existing liver disease, need for renal replacement therapy and higher APACHE III scores on admission. Patients receiving 4% HAS received a median volume of 500 mL [350-500] compared with 100 mL [100-200] in the 20% HAS group (P
The novel biased apelin receptor agonist MM07 is a potent inotrope and vasodilator in vivo AL Brame, JJ Maguire, A Dyson, M Singer, IB Wilkinson, AP Davenport
Healthcare cost trajectories before and after critical illness: a national data linkage cohort study NI Lone, TS Walsh
Glucose-insulin-potassium infusion for non-ischaemic cardiogenic shock: a proof of concept study TAC Snow, M Singer
P4 immunotherapy augments phagocyte bacterial killing in patients admitted to critical care with severe community-acquired pneumonia (abstract not available) B Morton, S Gore, M Bangert, E Dearing, R Parker, ID Welters, A Wright, G Rajam, EW Ades, A Kadioglu, SB Gordon
Superantigens in sepsis: effective treatment of staphylococcal enterotoxin B intoxication in the mouse (abstract not available) S Whitfield, C Green, J Risdall, C Taylor, A Carter, G Griffiths
16
The State of the Art 2014 Meeting
Research free paper presentations
Physiological and biochemical responses to fluid bolus therapy with 4% versus 20% human albumin solution in critically ill adults J Bannard-Smith*, N Glassford*†, P Alexander*, MJ Chan*, BT Wong*, M Lee*, G Crawford*, M Bailey†, R Bellomo* *Austin Health, Victoria, Australia. †Monash University, Alfred Hospital, Melbourne, Victoria, Australia Fluid bolus therapy (FBT) is common in critically ill patients. With the exception of traumatic brain injury, FBT with human albumin solution (HAS) appears safe and perhaps superior in severe sepsis.1 We aimed to compare the physiological and biochemical effects of FBT with 4% vs 20% HAS in critically ill adults. In a retrospective observational study at our tertiary intensive care unit, we obtained data for 202 critically ill patients receiving FBT with either 4% (n=101) or 20% (n=101) HAS according to clinician preference. We compared sequential biochemical and haemodynamic data at baseline, one, two and four hours after the administration of either 4% or 20% HAS. Patients receiving 20% HAS were generally sicker, with a higher incidence of pre-existing liver disease, need for renal replacement therapy and higher APACHE III scores on admission. Patients receiving 4% HAS received a median volume of 500 mL [350-500] compared with 100 mL [100-200] in the 20% HAS group (P
